TNFRSF9 and nasopharyngeal carcinoma: To explore the in vivo therapeutic efficacy of rhCD137L-MSNs in a clinically relevant setting, we employed PBMC-humanized NOD-scid (JInx) mice, bearing NPC of CD137-expressing (C666-CD137 or HK1-CD137) and -deficient (C666 or HK1) phenotype on the different flanks.